Skip to content
Peptilyze
CompoundsShopsCompareGuidesMethod
Metabolic research

Retatrutide studies

337 journal papers mention Retatrutide in the title or abstract. Here are the most cited, the latest, and a few facts about the literature.

Studies range from laboratory work to clinical trials. A paper listed here is not an endorsement and says nothing about whether Retatrutide is safe, effective or approved for any use.

Compare Retatrutide prices, from €29.99 →

Papers
337
211 articles, 126 reviews
Earliest paper
2019
Most papers in 2026 (163)
Open access
67%
free to read somewhere
Reviews
37%
of all papers listed

What kind of studies

Of 214 papers in PubMed that mention Retatrutide in the title or abstract, by the study type PubMed records. Categories overlap, so they do not add up to the total.

  • Randomized controlled trials10
  • Other clinical trials1
  • Meta-analyses and systematic reviews23
  • Other reviews131
  • Case reports3
  • Animal studies only11
  • Studies in humans129

Study types are tags assigned by publishers and PubMed indexers; very new papers are often not tagged yet, and a tag is not a quality rating. Retracted papers are excluded. Source: PubMed (NCBI).

Registered clinical studies

Studies on ClinicalTrials.gov that mention Retatrutide in their intervention details. A registration says a study is planned or running, not what it found.

Registered
34
Completed
22
Ongoing or planned
11
Phase 1
15
Phase 2
4
Phase 3
14
  1. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

    NCT06383390Active, not recruitingPhase 3started 2024-04-30

  2. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    NCT07165028RecruitingPhase 3started 2025-10-15

  3. A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

    NCT06982859Active, not recruitingPhase 1started 2025-06-02

  4. Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

    NCT06260722Active, not recruitingPhase 3started 2024-02-21

  5. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

    NCT07035093Active, not recruitingPhase 3started 2025-05-29

The five most recently updated studies. See all 34 on ClinicalTrials.gov. Source: ClinicalTrials.gov (U.S. National Library of Medicine). Studies are found by the compound's name, so a few may be about something else.

Papers per year

2019 to 2026, peak 163 papers in a year. The latest year may still be incomplete.

2019: 1 papers2020: 0 papers2021: 2 papers2022: 5 papers2023: 18 papers2024: 60 papers2025: 87 papers2026: 163 papers20192026

Where it is published

  1. Diabetes22 papers
  2. Diabetes Obesity and Metabolism8 papers
  3. Cureus7 papers
  4. Quality in Sport7 papers
  5. International Journal of Innovative Technologies in Social Science6 papers

The papers

ShowAllOpen accessReviews

Most citedName in the title

  1. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

    Ania M. Jastreboff, Lee M. Kaplan, Juan P. Frías et al. · New England Journal of Medicine · 2023

    Randomized trial · Phase 21,175 citations

  2. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

    Julio Rosenstock, Juan P. Frías, Ania M. Jastreboff et al. · The Lancet · 2023

    Randomized trial · Phase 2423 citations

  3. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

    Tamer Coşkun, Shweta Urva, William C. Roell et al. · Cell Metabolism · 2022

    Animal studyOpen access · CC BY-NC-ND316 citationsRead the open copy →

  4. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

    Arun Jayant Sanyal, Lee M. Kaplan, Juan P. Frías et al. · Nature Medicine · 2024

    Randomized trial · Phase 2Open access · CC BY315 citationsRead the open copy →

  5. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

    Shweta Urva, Tamer Coşkun, Mei Teng Loh et al. · The Lancet · 2022

    Randomized trial · Phase 1202 citations

  6. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial

    Tamer Coşkun, Qiwei Wu, Nanette Cathrin Schloot et al. · The Lancet Diabetes & Endocrinology · 2025

    Randomized trial · Phase 257 citations

  7. A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity

    Manmeet Kaur, Saurav Misra · European Journal of Clinical Pharmacology · 2024

    Review51 citations

  8. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials

    K. Giblin, Lee M. Kaplan, Virend Kristen Somers et al. · Diabetes Obesity and Metabolism · 2025

    Study in humansOpen access · CC BY-NC34 citationsRead the open copy →

  9. Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?

    Sheila Anne Doggrell · Expert Opinion on Investigational Drugs · 2023

    Study in humans34 citations

  10. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide

    Wenzhuo Li, Qingtong Zhou, Zhaotong Cong et al. · Cell Discovery · 2024

    Open access · CC BY32 citationsRead the open copy →

  11. Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence

    Muhammad Naeem, Laiba Imran, Umm E Salma Shabbar Banatwala · Health Science Reports · 2024

    Open access · CC BY30 citationsRead the open copy →

  12. Retatrutide—A Game Changer in Obesity Pharmacotherapy

    Vasiliki K. Katsi, Georgios Koutsopoulos, Christos Fragoulis et al. · Biomolecules · 2025

    ReviewOpen access · CC BY29 citationsRead the open copy →

  13. The novel GIP , GLP ‐1 and glucagon receptor agonist retatrutide delays gastric emptying

    Shweta Urva, Libbey S. O’Farrell, Yu Du et al. · Diabetes Obesity and Metabolism · 2023

    Study in humansOpen access · CC BY-NC-ND28 citationsRead the open copy →

  14. The power of three: Retatrutide's role in modern obesity and diabetes therapy

    Toufik Abdul‐Rahman, Poulami Roy, Fatma Kamal Ahmed et al. · European Journal of Pharmacology · 2024

    Review27 citations

  15. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials

    Alaa Abdrabou Abouelmagd, Amro Mamdouh Abdelrehim, Mohamed Nabih Bashir et al. · Baylor University Medical Center Proceedings · 2025

    ReviewOpen access25 citationsRead the open copy →

  16. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial

    HARPREET SINGH BAJAJ, Michelle Welch, Parag Shah et al. · The Lancet · 2026

    Randomized trial · Phase 323 citations

  17. The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity

    Hiddo J.L. Heerspink, Zeqing Lu, Yu Du et al. · Kidney International Reports · 2025

    Open access · CC BY-NC-ND23 citationsRead the open copy →

  18. Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice

    Jun Ma, Xiaoyan Hu, Wencheng Zhang et al. · Endocrine · 2024

    Animal study21 citations

  19. Efficacy and Safety of GLP ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA

    Binayak Sinha, Samit Ghosal · Obesity · 2025

    Systematic reviewOpen access19 citationsRead the open copy →

  20. Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP

    Xin Cui, Yueming Zhu, Lidan Zeng et al. · Advanced Science · 2025

    Study in humansOpen access · CC BY17 citationsRead the open copy →

  21. Retatrutide showing promise in obesity (and type 2 diabetes)

    Sheila Anne Doggrell · Expert Opinion on Investigational Drugs · 2023

    Review16 citations

  22. Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression

    Sandesh J. Marathe, Emily W. Grey, Margaret Sue Bohm et al. · npj Metabolic Health and Disease · 2025

    Open access · CC BY15 citationsRead the open copy →

  23. Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials

    Eric Pasqualotto, Rafael Oliva Morgado Ferreira, Matheus Pedrotti et al. · Metabolism Open · 2024

    ReviewOpen access · CC BY15 citationsRead the open copy →

  24. Retatrutide: a triple incretin receptor agonist for obesity management

    Avik Ray · Expert Opinion on Investigational Drugs · 2023

    Study in humans11 citations

  25. 679-P: The Novel GIP, GLP-1, and Glucagon Triple Receptor Agonist LY3437943 Exhibits Robust Efficacy in Preclinical Models of Obesity and Diabetes

    Tamer Coşkun, Julie S. Moyers, William C. Roell et al. · Diabetes · 2021

    10 citations

  26. Decreases in circulating ANGPTL3 /8 concentrations following retatrutide treatment parallel reductions in serum lipids

    Yi Wen, Deven Lemen, Yanzhu Lin et al. · Diabetes Obesity and Metabolism · 2025

    Clinical trial · Phase 2Open access · CC BY-NC9 citationsRead the open copy →

  27. Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis

    Jay Tewari, Khalid Ahmad Qidwai, Ajoy Tewari et al. · Expert Review of Clinical Pharmacology · 2025

    Meta-analysis9 citations

  28. Triple-Hormone Combination Retatrutide Induces 24% Body Weight Loss

    Emily Harris · JAMA · 2023

    Study in humans9 citations

  29. The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities

    Nila Ganamurali, Sarvesh Sabarathinam · Clinical Pharmacology in Drug Development · 2026

    ReviewOpen access · Public domain8 citationsRead the open copy →

  30. Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial

    IRIS A. GOETZ, Chisom Kanu, Anastasia Hoover et al. · Obesity Pillars · 2025

    Open access · CC BY-NC-ND8 citationsRead the open copy →

  31. Inotropic effects of retatrutide in isolated human atrial preparations

    Joachim Neumann, Undine Ahlrep, Britt Hofmann et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 2025

    Study in humansOpen access · CC BY7 citationsRead the open copy →

  32. 754-P: Effect of Retatrutide on Kidney Parameters in People with Type 2 Diabetes and/or Obesity—A Post-Hoc Analysis of Two Phase 2 Trials

    Hiddo J.L. Heerspink, ZEQING LU, Yu Du et al. · Diabetes · 2024

    7 citations

  33. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial

    Virginia Bellido, Carel Wynand le Roux, Elif Ilhan Ekinci et al. · The Lancet · 2026

    Randomized trial · Phase 36 citations

  34. At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide

    Kate Ruder · JAMA · 2023

    Study in humans6 citations

  35. Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia

    Timothy M. Piatkowski, Alison Craven, Samuel Cornell et al. · Drug and Alcohol Review · 2026

    Open access5 citationsRead the open copy →

  36. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease

    Hiddo J.L. Heerspink, Daniël H. van Raalte, Petter Bjornstad et al. · Nephrology Dialysis Transplantation · 2025

    Study in humansOpen access · CC BY5 citationsRead the open copy →

  37. The First Triple Agonist for Antiobesity: Retatrutide

    Lauren Tetelbaun, Jamie Ann Mullally, William H. Frishman · Cardiology in Review · 2024

    Review5 citations

  38. Multi-omic profiling reveals Retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair

    Qingyang Li, Weilun Cheng, Lei Zhang et al. · Diabetology & Metabolic Syndrome · 2026

    Open access · CC BY-NC-ND4 citationsRead the open copy →

  39. Retatrutide Shows Multiple Metabolic Benefits in Diet‐Induced Obese MASH Mouse and Hamster Models

    François Briand, Camille Le Cudennec, E. Grasset et al. · Obesity · 2026

    Animal studyOpen access · CC BY4 citationsRead the open copy →

  40. Retatrutide improves steatohepatitis in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge

    Greta Viebahn, Amit Khurana, Linton Freund et al. · American Journal of Physiology-Gastrointestinal and Liver Physiology · 2025

    Animal studyOpen access · CC BY4 citationsRead the open copy →

LatestName in title or abstract

  1. Suspected Drug-Induced Hepatocellular Injury Following Use of an Unregulated Injectable Product Marketed as Retatrutide: A Case Report

    Ahmed Elhassan, Isra Ali, Abu-Bekr Mohamed et al. · Cureus · 2026

    Open accessRead the open copy →

  2. EMERGING PHARMACOLOGICAL STRATEGIES IN OBESITY: FROM GLP-1 AGONISTS THROUGH TRIPLE INCRETIN THERAPY TO AMYLIN ANALOGS – NARRATIVE REVIEW

    Dagmara Laufer, Olga Klimczak, Filip Chodań et al. · Archiv Euromedica · 2026

    ReviewOpen accessRead the open copy →

  3. Eficácia e segurança da retatrutida, agonista triplo dos receptores de GIP, GLP-1 e glucagon, na obesidade e no diabetes mellitus tipo 2: Uma Revisão Sistemática

    João Pedro Medina Patrício, Isadora Brasil Fraga, Maria Eduarda Candido Santos et al. · Journal of Medical and Biosciences Research. · 2026

    Open access · CC BYRead the open copy →

  4. From Oxyntomodulin to Retatrutide: A Translational Review of Metabolic Polyagonism

    Héctor Iván Saldívar-Cerón, Daniela Maldonado-Trejo, Quetzal Chavez-Castañeda et al. · International Journal of Molecular Sciences · 2026

    Open access · CC BYRead the open copy →

  5. Glucose-dependent insulinotropic polypeptide (GIP) signaling in visceral and subcutaneous adipose tissue: implications for obesity and metabolic disease—a narrative review with a structured literature search

    Joanna Smarkusz-Zarzecka, Marcelina Radziszewska, Krzysztof Ksawery Gofron et al. · Reviews in Endocrine and Metabolic Disorders · 2026

    ReviewOpen access · CC BY-NC-NDRead the open copy →

  6. Synthesis of a Crystalline Acylated Lysine Building Block for Retatrutide Manufacture

    Jingyao Wang, Jing Teng, Emily J. Guinn et al. · Organic Process Research & Development · 2026

  7. Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea

    Ronald R. Grunstein, Virend Kristen Somers, Ali Azarbarzin et al. · New England Journal of Medicine · 2026

  8. GLP-1 RECEPTOR AGONISTS AND THYROID DISEASE: FROM MECHANISM TO CLINICAL PRACTICE

    Aleksandra Milewska, Anna Bociąg, Konrad Kowalski et al. · International Journal of Innovative Technologies in Social Science · 2026

    Open access · CC BYRead the open copy →

  9. Effects of GLP-1–Related Therapies on Lean Mass and Body Composition: A Narrative Review

    Amanda Palmieri Ataei, Nima Ataei · Journal of Fitness Wellness and Human Performance · 2026

    Review

  10. Retatrutide treatment in streptozotocin-induced diabetic rats: renal inflammatory cytokines, HIF‑1α expression, and histopathological injury profile

    Ulya Keskin, Eslem Altın, Fikriye Yasemin Özatik et al. · Journal of Molecular Histology · 2026

    Animal studyOpen access · CC BYRead the open copy →

  11. GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?

    Ademir Carvalho Leite, Howard Lopes Ribeiro · Acta Diabetologica · 2026

    ReviewOpen access · CC BYRead the open copy →

  12. Incretin-Based Polypharmacology and the Redefinition of Cardiometabolic Medicine

    Sujit B. Kanoia, Anuansh Tiwari, Syed Wajahat Abbas Rizvi et al. · Journal of Pharmaceutical and Biopharmaceutical Research · 2026

    Open access · CC BY-NCRead the open copy →

  13. Self-Reported Adverse Effects Among Social Media Users Taking Nonapproved Retatrutide

    Neil K. R. Sehgal, Jena Shaw Tronieri, Benjamin M. Rader et al. · JAMA Network Open · 2026

    Open accessRead the open copy →

  14. From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease

    Christiano Argano, Dalila Maggio, Chiara Pollicino et al. · Frontiers in Pharmacology · 2026

    ReviewOpen access · CC BYRead the open copy →

  15. The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications

    Zhiyu Chen, Ying Zhou, Gang Li et al. · Journal of Diabetes & Metabolic Disorders · 2026

    ReviewOpen accessRead the open copy →

  16. Progress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective

    Ishtiaque Ahmad, Sarfuddin Azmi, Monirah Abdulrahman Albabtain et al. · Pharmaceutics · 2026

    ReviewOpen access · CC BYRead the open copy →

  17. Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence

    Diana-Maria Mateescu, Ionuţ Dragoş Căpraru, Bogdan Enache et al. · Pharmaceutics · 2026

    ReviewOpen access · CC BYRead the open copy →

  18. Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain

    Rita Rubin · JAMA · 2026

  19. GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases

    Elena Koceva, Gert N. Moll · European Journal of Pharmacology · 2026

    ReviewOpen access · CC BYRead the open copy →

  20. Repurposing Retatrutide for Neuroprotection in Parkinson’s Disease: A Comprehensive Review

    Sivakumar G., Thilagavathi K., Narmatha K. K. et al. · International Journal of Innovative Science and Research Technology (IJISRT) · 2026

    Open accessRead the open copy →

  21. The metabolic paradigm shift in gastroenterology and hepatology: Clinical applications of incretin-based co-agonists

    Abdulrahman Ismaiel, Dan Lucian Dumitrascu · Best Practice & Research Clinical Gastroenterology · 2026

    Open access · CC BY-NCRead the open copy →

  22. Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide

    Raphael M. Buzzi, Lars Christian Huber · BMJ Case Reports · 2026

    Case reportOpen access · CC BY-NCRead the open copy →

  23. Retatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2?

    Jens Juul Holst · The Lancet · 2026

  24. Dual and triple incretin agonists in type 2 diabetes: A new frontier in metabolic therapy

    Syed Afzal Uddin Biyabani, Neelkantreddy Patil, Pooja V. Salimath et al. · International Journal of Pharmacy and Pharmaceutical Science · 2026

    Open accessRead the open copy →

  25. GLP-1, GIP, and Glucagon Receptor Agonism at the Obesity–Neurodegeneration Interface: A Narrative Review

    Elena Popa, Andrei Emilian Popa, Vladimir Poroch et al. · International Journal of Molecular Sciences · 2026

    ReviewOpen access · CC BYRead the open copy →

  26. Gastrointestinal adverse effects of GLP‐1 receptor agonists and dual GIP/GLP‐1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents

    Fnu Vikash, Muhammad Ehsan, Sara Osorio Valencia et al. · Nutrition in Clinical Practice · 2026

    ReviewOpen access · CC BY-NCRead the open copy →

  27. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial

    Virginia Bellido, Carel Wynand le Roux, Elif Ilhan Ekinci et al. · The Lancet · 2026

    Randomized trial · Phase 36 citations

  28. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity

    Ania M. Jastreboff, Lee M. Kaplan, Melanie Jane Davies et al. · New England Journal of Medicine · 2026

    2 citations

  29. Efficacy and Safety of Dual GLP ‐1/Glucagon Receptor Agonism in Overweight and Obesity: A Class‐Specific Systematic Review and Meta‐Analysis

    Muhammad Maaz Amjad, Muhammad Mustafa Khan, Fatima Sarwar et al. · Diabetes Obesity and Metabolism · 2026

    ReviewOpen accessRead the open copy →

  30. BEYOND GLYCEMIC CONTROL: ORGAN-PROTECTIVE EFFECTS AND SAFETY PROFILE OF GLP-1 RECEPTOR AGONISTS – A COMPREHENSIVE REVIEW

    Magdalena Bukowska, Katarzyna Otrębska, Dominika Lewandowska et al. · International Journal of Innovative Technologies in Social Science · 2026

    Open access · CC BYRead the open copy →

  31. Future GLP-1 receptor co-agonists and their cardiac effects

    Joachim Neumann, Uwe Kirchhefer, Britt Hofmann et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 2026

    Open access · CC BYRead the open copy →

  32. The Possible Hematological Cost of Metabolic Success: Do Incretin-Based Therapies Silently Trigger Anemia?

    Maja Mizdrak, Darko Batistic, Ivan Mizdrak · Medical Sciences · 2026

    ReviewOpen access · CC BYRead the open copy →

  33. Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats

    Jonas Petersen, Christoffer Merrild, Stephanie Kjærulff Holm et al. · Nature Metabolism · 2026

    Animal studyOpen access · CC BYRead the open copy →

  34. Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists

    Dorota Bartkowiak, Barlomiej Jakubczyk, Adam Lasota et al. · Cureus · 2026

    ReviewOpen access · CC BYRead the open copy →

  35. ADVANCES IN OBESITY PHARMACOTHERAPY: CURRENT STATE AND FUTURE PERSPECTIVES

    Aleksandra Wielogórska, Olga Stasiak, Filip Kowalik et al. · International Journal of Innovative Technologies in Social Science · 2026

    Open access · CC BYRead the open copy →

  36. Single or multiple nutritional hormone receptor modulators for chronic kidney disease

    Hiddo J.L. Heerspink · Clinical Kidney Journal · 2026

    ReviewOpen access · CC BY-NCRead the open copy →

  37. Incretin-based therapies in diabetic kidney disease: toward integrated cardio-kidney-metabolic disease modification

    Yaeni Kim, Eun Young Lee, On behalf of the Korean Diabetic Kidney Disease Study Group · Kidney Research and Clinical Practice · 2026

    Open access · CC BY-NC-NDRead the open copy →

  38. Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review

    Irma Melyani Puspitasari, Dimas Setyadi Putra, Alifa Nisa Deliyana et al. · Diabetes Metabolic Syndrome and Obesity · 2026

    ReviewOpen access · CC BY-NCRead the open copy →

  39. Pharmacological management of obesity: Current landscape and emerging therapies

    Shubham Atal, Chirag Agrawal, Rahul Gupta et al. · Indian Journal of Pharmacology · 2026

    ReviewOpen access · CC BY-NC-NDRead the open copy →

  40. Glucagon is terug: survodutide opent nieuw hoofdstuk in obesitas en MASLD

    Marcel H.A. Muskiet · Nederlands Tijdschrift voor Diabetologie · 2026

    Open access · CC BY-NC-NDRead the open copy →

Each list shows up to 40 papers.See all 337 on OpenAlex. Source: OpenAlex (CC0), journal articles and reviews with a DOI, retractions excluded, refreshed weekly, last 4 Nov 2026, 08:30 UTC. Papers are listed by their metadata only; follow the links to read them. A license shown on an open copy is the license the publisher or repository states for that copy.